MRI measures should be a primary outcome endpoint in Phase III randomized,controlled trials in multiple sclerosis: Yes

Filippi M Rocca MA Barkhof F . Association between pathological and MRI findings in multiple sclerosis. Lancet Neurol 2012; 11: 349–360.

Petkau J Reingold S Held U . Magnetic resonance imaging as a surrogate outcome for multiple sclerosis relapses. Mult Scler 2008;14: 770–778.

Sormani MP Bonzano L Roccatagliata L . Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: A meta-analytic approach. Ann Neurol 2009; 65: 268–275.

Sormani MP Bruzzi P . Validation of MRI as a surrogate for relapses in multiple sclerosis: A meta-analysis of randomized trials. Lancet Neurol 2013; 12: 669–676.

Sormani MP Stubinski B Cornelisse P . Magnetic resonance active lesions as individual-level surrogate for relapses in multiple sclerosis. Mult Scler 2011; 17: 541–549.

Verhey LH Signori A Arnold DL . Clinical and MRI activity as determinants of sample size for pediatric multiple sclerosis trials. Neurology 2013. [Epub ahead of Print; August 21, 2013 as 10.1212/WNL.0b013e3182a6cb9b].

Sormani MP Bonzano L Roccatagliata L . Surrogate endpoints for EDSS worsening in multiple sclerosis: A meta-analytic approach. Neurology 2010; 75: 302–309.

Barkhof F Calabresi P Miller DH . Imaging outcomes for neuroprotection and repair in multiple sclerosis trials. Nat Rev Neurol 2009; 5: 256–266.

Sormani MP Arnold DL De Stefano N . Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis. Ann Neurol 2013. doi: 10.1002/ana.24018.